The U.S. Food and Drug Administration on Monday approved the first injectable medication to lower the risk of contracting HIV, or the human immunodeficiency virus.
HIV attacks the body’s immune system and causes AIDS (acquired immunodeficiency syndrome) if not treated.
The FDA-approved medication is an injectable form of GlaxoSmithKline Plc’s cabotegravir drug. The injection, called Apretude (cabotegravir extended-release injectable suspension), is given every two months as a preventative treatment, or pre-exposure prophylaxis (PrEP), to reduce the risk of sexually-acquired HIV.
After an initial injection, the drug is administered one month later, and then every two months thereafter.
Hmmmmm. That dosage schedule sounds suspiciously like the horse paste schedule...
Even the CDC said the fags didn’t need to wear a condom anymore.
#NoMask